Search Within

Dana Elizabeth Rathkopf

  1. "Susan Slovin"
Formats
  1. Meeting Abstract (35)
  2. Journal Article (24)
Groups
  1. Department of Medicine (59)
  2. Genitourinary Oncology Service (59)
  3. Hematologic Malignancies, Division of (59)
  4. Solid Tumor Oncology Division (59)
  5. GSK Faculty (34)
  6. Department of Pathology and Laboratory Medicine (24)

More Groups

People
  1. Susan Slovin (59)
  2. Howard Scher (54)
  3. Michael Morris (52)
  4. Daniel Danila (35)
  5. Karen Autio (22)
  6. Wassim Abida (19)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (4)
  4. 2021 (3)
  5. 2020 (3)
  6. 2019 (8)

More Years

Publications
  1. Journal of Clinical Oncology (36)
  2. Annals of Oncology (4)
  3. Clinical Cancer Research (4)
  4. Cancer (2)
  5. Clinical Genitourinary Cancer (2)
  6. JCO Precision Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (38)
  2. American Association for Cancer Research (5)
  3. Oxford University Press (4)
  4. Springer (3)
  5. Elsevier Inc. (2)
  6. Wiley Blackwell (2)

More Publishers

Results (59)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
    Meeting Abstract

    Lang, J. M.; Tagawa, S. T.; Slovin, S.; Sperger, J. M.; Schehr, J. L.; Stahlfeld, C.; Hintz, A. M.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer
    Journal Article

    Lenis, A. T.; Ravichandran, V.; Brown, S.; Alam, S. M.; Katims, A.; Truong, H.; Reisz, P. A.; Vasselman, S.; Nweji, B.; Autio, K. A.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Gene-based confirmatory germline testing following tumor-only sequencing of prostate cancer
    Journal Article

    Truong, H.; Breen, K.; Nandakumar, S.; Sjoberg, D. D.; Kemel, Y.; Mehta, N.; Lenis, A. T.; Reisz, P. A.; Carruthers, J.; Benfante, N.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
    Meeting Abstract

    Lang, J.; Tagawa, S. T.; Slovin, S.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; Autio, K.; Xiao, H.; Molina, A. M.; Eickhoff, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality
    Journal Article

    Keegan, N. M.; Vasselman, S. E.; Barnett, E. S.; Nweji, B.; Carbone, E. A.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
    Prostate (2022)

    Fulltext@MSK | Save
  • Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality
    Meeting Abstract

    Keegan, N. M.; Vasselman, S. E.; Barnett, E.; Nweji, B.; Carbone, E.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
    Journal Article

    Stopsack, K. H.; Nandakumar, S.; Arora, K.; Nguyen, B.; Vasselman, S. E.; Nweji, B.; McBride, S. M.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Interim results of AASUR: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA plus P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa)
    Meeting Abstract

    McBride, S. M.; Spratt, D. E.; Kollmeier, M.; Abida, W.; Xiao, H.; Slovin, S. F.; Paller, C. J.; Deville, C.; Den, R. B.; Hearn, J. W. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy
    Journal Article

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
    European Urology Open Science (2021)

    Fulltext@MSK | Save
  • Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A phase I study
    Journal Article

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S. W.; Slovin, S. F.; Adamow, M.; Blinder, V. S.; Brahmachary, M.; Carlsen, M.; Comen, E.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save